Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network.
DLBCLs
EBV latency III B-cells
PD-L1
actin network
fucoidan
very-low-molecular-weight fucoidan
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
18 Feb 2023
18 Feb 2023
Historique:
received:
26
01
2023
revised:
13
02
2023
accepted:
15
02
2023
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) infects 95% of the world's population and persists latently in the body. It immortalizes B-cells and is associated with lymphomas. LCLs (lymphoblastoid cell lines, EBV latency III B-cells) inhibit anti-tumoral T-cell response following PD-L1 overexpression (programmed death-ligand 1 immune checkpoint). Many cancer cells, including some DLBCLs (diffuse large B-cell lymphomas), also overexpress PD-L1. Immunotherapies are based on inhibition of PD-L1/PD-1 interactions but present some dose-dependent toxicities. We aim to find new strategies to improve their efficiency by decreasing PD-L1 expression. Fucoidan, a polysaccharide extracted from brown seaweed, exhibits immunomodulatory and anti-tumor activities depending on its polymerization degree, but data are scarce on lymphoma cells or immune checkpoints. LCLs and DLBCLs cells were treated with native fucoidan (
Identifiants
pubmed: 36827173
pii: md21020132
doi: 10.3390/md21020132
pmc: PMC9963441
pii:
doi:
Substances chimiques
CD274 protein, human
0
B7-H1 Antigen
0
fucoidan
9072-19-9
Actins
0
Polysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ligue régionale contre le cancer Haute-Vienne France
ID : MM/CF n° 8
Organisme : Ligue régionale contre le cancer Haute-Vienne France
ID : MM/CF n° 22
Références
Cell Commun Signal. 2019 Aug 5;17(1):89
pubmed: 31382969
Mar Drugs. 2020 Jun 24;18(6):
pubmed: 32599714
Mar Drugs. 2013 Aug 19;11(8):2982-99
pubmed: 23966032
Mol Cell. 2019 Nov 7;76(3):359-370
pubmed: 31668929
Mar Drugs. 2015 Apr 14;13(4):2327-46
pubmed: 25874926
Front Immunol. 2019 Aug 27;10:2022
pubmed: 31507611
Cancer Manag Res. 2020 Jul 23;12:6195-6207
pubmed: 32884336
J Immunol. 2019 Sep 15;203(6):1665-1674
pubmed: 31434708
Glycobiology. 2007 May;17(5):541-52
pubmed: 17296677
Phytother Res. 2022 Feb;36(2):761-777
pubmed: 34962325
J Immunol. 2012 Jul 1;189(1):181-90
pubmed: 22661084
Nitric Oxide. 2011 Nov 30;25(4):407-15
pubmed: 22024029
Mar Drugs. 2014 Jan 28;12(2):851-70
pubmed: 24477286
Mar Drugs. 2013 Jul 04;11(7):2347-64
pubmed: 23880928
Biomol Ther (Seoul). 2015 May;23(3):225-32
pubmed: 25995820
Adv Exp Med Biol. 2020;1248:455-483
pubmed: 32185722
Nutr Cancer. 2017 Nov-Dec;69(8):1234-1244
pubmed: 29043842
Mar Drugs. 2019 Feb 27;17(3):
pubmed: 30818840
Int J Mol Sci. 2021 Aug 24;22(17):
pubmed: 34502035
Front Oncol. 2019 Aug 06;9:713
pubmed: 31448229
Mar Drugs. 2015 Sep 16;13(9):5920-46
pubmed: 26389927
PLoS One. 2014 Jun 09;9(6):e99396
pubmed: 24911024
Carbohydr Polym. 2015 Nov 5;132:378-96
pubmed: 26256362
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Mar Drugs. 2021 Dec 22;20(1):
pubmed: 35049864
Front Cell Dev Biol. 2021 Aug 09;9:733246
pubmed: 34434936
Blood. 2015 Nov 5;126(19):2171-2
pubmed: 26542250
Int J Biol Macromol. 2011 Oct 1;49(3):331-6
pubmed: 21624396
Mar Drugs. 2015 Feb 19;13(3):1084-104
pubmed: 25706632
Blood. 2008 Mar 15;111(6):3220-4
pubmed: 18203952
Adv Exp Med Biol. 2020;1248:325-346
pubmed: 32185717
Biology (Basel). 2020 Nov 07;9(11):
pubmed: 33171868
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Curr Oncol Rep. 2018 Jul 31;20(9):72
pubmed: 30066230
Int J Biol Macromol. 2021 Jun 30;181:180-192
pubmed: 33771548
Nat Commun. 2022 Jan 19;13(1):392
pubmed: 35046403
Mar Drugs. 2022 Feb 28;20(3):
pubmed: 35323480
Front Immunol. 2021 Aug 31;12:651634
pubmed: 34531847
J Hematol Oncol. 2022 Mar 12;15(1):24
pubmed: 35279217
Curr Opin Microbiol. 2009 Jun;12(3):261-73
pubmed: 19467920
Acta Biochim Biophys Sin (Shanghai). 2015 Nov;47(11):925-31
pubmed: 26358321
Trends Cell Biol. 2018 Sep;28(9):685-697
pubmed: 29759816
Cell Mol Life Sci. 2013 Jun;70(12):2099-121
pubmed: 22986507
Mar Drugs. 2019 Aug 05;17(8):
pubmed: 31387230
Mar Drugs. 2020 Feb 08;18(2):
pubmed: 32046368
Am J Hematol. 2021 May 1;96(5):617-629
pubmed: 33661537
Mar Drugs. 2019 Jul 19;17(7):
pubmed: 31331053
Transl Oncol. 2021 Jun;14(6):101051
pubmed: 33761369
Acta Pharm Sin B. 2022 Mar;12(3):1041-1053
pubmed: 35530130
Mar Drugs. 2021 May 10;19(5):
pubmed: 34068561
Mar Drugs. 2017 Apr 21;15(4):
pubmed: 28430159
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Clin Transl Med. 2019 May 1;8(1):15
pubmed: 31041568
Mar Drugs. 2020 Apr 28;18(5):
pubmed: 32354032
Biomedicines. 2021 Nov 16;9(11):
pubmed: 34829931
Cancers (Basel). 2021 Apr 14;13(8):
pubmed: 33919917
Integr Cancer Ther. 2017 Dec;16(4):572-584
pubmed: 29096568
J Virol. 2014 Oct;88(20):12065-76
pubmed: 25122803
Mar Drugs. 2016 Jun 24;14(7):
pubmed: 27347980
Int J Biol Macromol. 2022 May 31;208:230-242
pubmed: 35337909
Mar Drugs. 2018 Jun 04;16(6):
pubmed: 29867001
Polymers (Basel). 2020 Oct 13;12(10):
pubmed: 33066186
Cancers (Basel). 2020 Jan 18;12(1):
pubmed: 31963677
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Mar Drugs. 2020 Feb 27;18(3):
pubmed: 32120789
Mil Med Res. 2021 Nov 8;8(1):56
pubmed: 34743730
Cancer Cell Int. 2020 May 7;20:154
pubmed: 32410882
Mar Drugs. 2019 Mar 20;17(3):
pubmed: 30897733
PLoS One. 2012;7(11):e50624
pubmed: 23226337
Mol Carcinog. 2010 Aug;49(8):771-82
pubmed: 20572161